Last reviewed · How we verify

Wuhan BravoVax Co., Ltd. — Portfolio Competitive Intelligence Brief

Wuhan BravoVax Co., Ltd. pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Recombinant Zoster Vaccine Recombinant Zoster Vaccine marketed
Zoster Vaccine Recombinant, Adjuvanted Zoster Vaccine Recombinant, Adjuvanted marketed Recombinant subunit vaccine with adjuvant Varicella-zoster virus glycoprotein E (gE) Immunology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. GlaxoSmithKline · 1 shared drug class
  2. Wuerzburg University Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Wuhan BravoVax Co., Ltd.:

Cite this brief

Drug Landscape (2026). Wuhan BravoVax Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/wuhan-bravovax-co-ltd. Accessed 2026-05-18.

Related